Preclinical disposition of MGS0274 besylate, a prodrug of a potent group II metabotropic glutamate receptor agonist MGS0008 for the treatment of schizophrenia

Preclinical disposition of MGS0274 besylate, a prodrug of a potent group II metabotropic glutamate receptor agonist MGS0008 for the treatment of schizophrenia

Abstract MGS0274 besylate is an ester‐based lipophilic prodrug of a metabotropic glutamate (mGlu) 2 and mGlu3 receptor agonist MGS0008 and being developed for the treatment of schizophrenia. We investigated the disposition of these compounds in rats and monkeys and in vitro metabolism in humans to e...

Full description

Bibliographic Details
Main Authors: Kohnosuke Kinoshita, Motoki Ochi, Katsuya Iwata, Misako Fukasawa, Jun‐ichi Yamaguchi
Format: Article
Language:English
Published: Wiley 2019-10-01
Series:Pharmacology Research & Perspectives
Subjects:
mGlu2/3 receptor
MGS0008
MGS0274 besylate
prodrug
Online Access:https://doi.org/10.1002/prp2.520

Similar Items

Similar Items